{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:38:03Z","timestamp":1791171483417,"version":"4.1.0"},"reference-count":103,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/crd.0b013e3181f52a7f","type":"journal-article","created":{"date-parts":[[2010,10,5]],"date-time":"2010-10-05T05:18:05Z","timestamp":1286255885000},"page":"298-304","source":"Crossref","is-referenced-by-count":75,"title":["The Pleiotropic Effects of the Hydroxy-Methyl-Glutaryl-CoA Reductase Inhibitors in Cardiovascular Disease"],"prefix":"10.1097","volume":"18","author":[{"given":"Christos G.","family":"Mihos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bmj.321.7267.983","article-title":"Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials.","volume":"321","author":"Pignone","year":"2000","journal-title":"BMJ"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.","volume":"339","author":"Tonkin","year":"1998","journal-title":"N Engl J Med"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.jcbfm.9600116","article-title":"Statins and stroke.","volume":"25","author":"Endres","year":"2005","journal-title":"J Cereb Blood Flow Metab"},{"key":"R4-5-20210203","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0167-5273(02)00195-X","article-title":"Beyond lipid lowering: the role of statins in vascular protection.","volume":"86","author":"Liao","year":"2002","journal-title":"Int J Cardiol"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1755-5922.2009.00103.x","article-title":"Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappa B pathway.","volume":"28","author":"Li","year":"2010","journal-title":"Cardiovasc Ther"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/0253-7613.15106","article-title":"Pleiotropic effects of statins.","volume":"37","author":"Tandon","year":"2005","journal-title":"Indian J Pharmacol"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00041433-200212000-00005","article-title":"Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence.","volume":"13","author":"Rosenson","year":"2002","journal-title":"Curr Opin Lipidol"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/eurheartj\/ehl277","article-title":"Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.","volume":"27","author":"Link","year":"2006","journal-title":"Eur Heart J"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1161\/hc2401.092816","article-title":"Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease.","volume":"103","author":"Vasa","year":"2001","journal-title":"Circulation"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.amjcard.2009.05.009","article-title":"Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome.","volume":"104","author":"Rod\u00e9s-Cabau","year":"2009","journal-title":"Am J Cardiol"},{"key":"R11-5-20210203","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00129784-200707020-00005","article-title":"Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials.","volume":"7","author":"Bavry","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"key":"R14-5-20210203","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jacc.2009.06.041","article-title":"Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).","volume":"54","author":"Cleland","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1586\/erc.09.119","article-title":"Rosuvastatin along the cardiovascular continuum: from Jupiter to Aurora.","volume":"7","author":"Barrios","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cardfail.2005.06.439","article-title":"Atorvastatin therapy increases heart rate variability, decreased QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure.","volume":"11","author":"Vrtovec","year":"2005","journal-title":"J Card Fail"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijcard.2008.11.030","article-title":"Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure.","volume":"140","author":"Xie","year":"2010","journal-title":"Int J Cardiol"},{"key":"R18-5-20210203","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.amjcard.2009.07.055","article-title":"Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure.","volume":"104","author":"Lipinski","year":"2009","journal-title":"Am J Cardiol"},{"key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.109.849117","article-title":"Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis.","volume":"120","author":"McMurray","year":"2009","journal-title":"Circulation"},{"key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ahj.2007.02.002","article-title":"Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).","volume":"153","author":"Dickinson","year":"2007","journal-title":"Am Heart J"},{"key":"R21-5-20210203","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijcard.2006.07.106","article-title":"Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.","volume":"119","author":"Krum","year":"2007","journal-title":"Int J Cardiol"},{"key":"R22-5-20210203","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.amjcard.2006.12.080","article-title":"Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]).","volume":"99","author":"Domanski","year":"2007","journal-title":"Am J Cardiol"},{"key":"R23-5-20210203","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1096\/fj.05-5067fje","article-title":"Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits.","volume":"20","author":"Muhlhauser","year":"2006","journal-title":"FASEB J"},{"issue":"suppl","key":"R24-5-20210203","first-page":"II","article-title":"Statin prevents structural and electrical remodeling in rat hypertensive heart failure induced by chronic inhibition of NO synthesis.","volume":"116","author":"Okazaki","year":"2007","journal-title":"Circulation"},{"key":"R25-5-20210203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cardiores.2004.01.018","article-title":"The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.","volume":"62","author":"Kumagai","year":"2004","journal-title":"Cardiovasc Res"},{"key":"R26-5-20210203","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.amjcard.2003.08.040","article-title":"Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease.","volume":"92","author":"Young-Xu","year":"2003","journal-title":"Am J Cardiol"},{"key":"R27-5-20210203","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.amjcard.2010.01.341","article-title":"Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease.","volume":"105","author":"Kulik","year":"2010","journal-title":"Am J Cardiol"},{"key":"R28-5-20210203","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.amjcard.2003.08.023","article-title":"Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion.","volume":"92","author":"Siu","year":"2003","journal-title":"Am J Cardiol"},{"key":"R29-5-20210203","first-page":"2988","article-title":"Effect of atorvastatin on postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting.","volume":"89","author":"Sun","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R30-5-20210203","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.amjcard.2009.07.045","article-title":"Impact of prior statin therapy on arrhythmic events in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events [GRACE]).","volume":"104","author":"Vedre","year":"2009","journal-title":"Am J Cardiol"},{"issue":"suppl","key":"R31-5-20210203","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1093\/eurheartj\/sun014","article-title":"Overview of clinical trials on calcific aortic stenosis.","volume":"10","author":"Pedersen","year":"2008","journal-title":"Eur Heart J"},{"key":"R32-5-20210203","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/hc4301.098249","article-title":"Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis.","volume":"104","author":"Novaro","year":"2001","journal-title":"Circulation"},{"key":"R33-5-20210203","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0002-9149(01)01821-5","article-title":"Association of coronary risk factors and use of statins with progression of mild valvular stenosis in older persons.","volume":"88","author":"Aronow","year":"2001","journal-title":"Am J Cardiol"},{"key":"R34-5-20210203","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0735-1097(02)02496-8","article-title":"Association of cholesterol levels, hydroxymethylglutaryl coenzyme A reductase inhibitor treatment, and progression of aortic stenosis in the community.","volume":"40","author":"Bellamy","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R35-5-20210203","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacc.2006.07.072","article-title":"Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.","volume":"49","author":"Moura","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R36-5-20210203","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.","volume":"352","author":"Cowell","year":"2005","journal-title":"N Eng J Med"},{"key":"R37-5-20210203","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.","volume":"359","author":"Rossebo","year":"2008","journal-title":"N Eng J Med"},{"key":"R38-5-20210203","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial.","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"key":"R42-5-20210203","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/1074248409340157","article-title":"Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy.","volume":"14","author":"Desai","year":"2009","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R43-5-20210203","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1074248409351408","article-title":"Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy.","volume":"15","author":"Desai","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R44-5-20210203","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.amjcard.2008.02.103","article-title":"Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators.","volume":"102","author":"Lai","year":"2008","journal-title":"Am J Cardiol"},{"key":"R45-5-20210203","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jacc.2005.09.053","article-title":"Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II.","volume":"47","author":"Vyas","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R46-5-20210203","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.amjcard.2009.12.057","article-title":"Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure.","volume":"105","author":"Desai","year":"2010","journal-title":"Am J Cardiol"},{"key":"R47-5-20210203","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jcin.2009.11.021","article-title":"Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.","volume":"3","author":"Kim","year":"2010","journal-title":"J Am Coll Cardiol Interv"},{"key":"R48-5-20210203","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1161\/01.CIR.0000137828.06205.87","article-title":"Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial.","volume":"110","author":"Pasceri","year":"2004","journal-title":"Circulation"},{"key":"R49-5-20210203","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10557-010-6224-1","article-title":"Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin.","volume":"24","author":"Cay","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"key":"R51-5-20210203","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/j.jacc.2009.07.005","article-title":"Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.","volume":"54","author":"Briguori","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R52-5-20210203","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.jacc.2009.09.010","article-title":"Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.","volume":"54","author":"Gibson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R53-5-20210203","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.atherosclerosis.2009.12.001","article-title":"Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (extended-ESTABLISH trial): a follow-up study.","volume":"210","author":"Dohi","year":"2010","journal-title":"Atherosclerosis"},{"key":"R54-5-20210203","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jacc.2009.05.028","article-title":"Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results from the ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) randomized trial.","volume":"54","author":"Di Sciascio","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R55-5-20210203","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1161\/CIRCULATIONAHA.108.799445","article-title":"Impact of statin use on outcomes after coronary artery bypass graft surgery.","volume":"118","author":"Kulik","year":"2008","journal-title":"Circulation"},{"key":"R56-5-20210203","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/MCA.0b013e3283142607","article-title":"Statin therapy is associated with reduced total and cardiovascular mortality after coronary artery bypass grafting surgery.","volume":"19","author":"Papathanasiou","year":"2008","journal-title":"Coron Artery Dis"},{"key":"R57-5-20210203","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/01.CCM.0000201407.89977.EA","article-title":"Effects of atorvastatin on systemic immune inflammatory response after coronary artery bypass surgery.","volume":"34","author":"Chello","year":"2006","journal-title":"Crit Care Med"},{"key":"R58-5-20210203","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1177\/147323000803600611","article-title":"Preoperative atorvastatin therapy to decrease the systemic immune inflammatory response after coronary artery bypass grafting.","volume":"36","author":"Dereli","year":"2008","journal-title":"J Int Med Res"},{"key":"R59-5-20210203","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-2008-1039107","article-title":"Reduced P-selectin in hearts pretreated with fluvastatin: a novel benefit for patients undergoing open heart surgery.","volume":"57","author":"Berkan","year":"2009","journal-title":"Thorac Cardiovasc Surg"},{"key":"R60-5-20210203","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1067\/mva.2002.122029","article-title":"Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration.","volume":"36","author":"Porter","year":"2002","journal-title":"J Vasc Surg"},{"key":"R61-5-20210203","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jss.2007.08.017","article-title":"Pitavastatin inhibits intimal hyperplasia in rabbit vein graft.","volume":"148","author":"Fujita","year":"2008","journal-title":"J Surg Res"},{"key":"R62-5-20210203","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/FJC.0b013e3181c37d4d","article-title":"Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized controlled study.","volume":"55","author":"Spadaccio","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"R63-5-20210203","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/eurheartj\/ehn198","article-title":"Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients.","volume":"29","author":"Liakopoulos","year":"2008","journal-title":"Eur Heart J"},{"key":"R64-5-20210203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1749-8090-5-8","article-title":"Preoperative statin is associated with decreased operative mortality in high-risk coronary artery bypass patients.","volume":"5","author":"Magovern","year":"2010","journal-title":"J Cardiothorac Surg"},{"key":"R65-5-20210203","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.jvca.2009.02.008","article-title":"Perioperative statin therapy is associated with a significant and dose-dependent reduction of adverse cardiovascular outcomes after coronary artery bypass graft surgery.","volume":"23","author":"Ouattara","year":"2009","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R66-5-20210203","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1755-5922.2009.00124.x","article-title":"Preoperative statin therapy decreases risk of postoperative renal insufficiency.","volume":"28","author":"Virani","year":"2010","journal-title":"Cardiovasc Ther"},{"key":"R67-5-20210203","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/j.jvca.2008.11.005","article-title":"Preoperative statin administration is associated with lower mortality and decreased need for postoperative hemodialysis in patients undergoing coronary artery bypass graft surgery.","volume":"23","author":"Huffmyer","year":"2009","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R68-5-20210203","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1185\/030079907X210570","article-title":"Preoperative statins and infectious complications following cardiac surgery.","volume":"23","author":"Coleman","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R69-5-20210203","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1010-7940(99)00034-2","article-title":"Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG.","volume":"15","author":"Christenson","year":"1999","journal-title":"Eur J Cardiothorac Surg"},{"key":"R70-5-20210203","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ejvs.2008.12.009","article-title":"In vivo confirmation of the role of statins in reducing nitric oxide and C-reactive protein levels in peripheral arterial disease.","volume":"37","author":"Aguilar","year":"2009","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R71-5-20210203","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1358836X9900400104","article-title":"Decrease in P-selectin levels in patients with hypercholesterolemia and peripheral arterial occlusive disease after lipid-lowering treatment.","volume":"4","author":"Kirk","year":"1999","journal-title":"Vasc Med"},{"key":"R72-5-20210203","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jvs.2007.05.039","article-title":"Platelet activation increases the severity of peripheral arterial disease: implications for clinical management.","volume":"46","author":"Rajagopalan","year":"2007","journal-title":"J Vasc Surg"},{"key":"R73-5-20210203","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.","volume":"45","author":"Bulbulia","year":"2007","journal-title":"J Vasc Surg"},{"key":"R74-5-20210203","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jvs.2007.11.056","article-title":"Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia.","volume":"47","author":"Schanzer","year":"2008","journal-title":"J Vasc Surg"},{"key":"R74A-5-20210203","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.archger.2009.09.042","article-title":"Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins.","volume":"51","author":"Desai","year":"2010","journal-title":"Arch Geront Geriat"},{"key":"R75-5-20210203","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jvs.2007.01.024","article-title":"The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease.","volume":"45","author":"Feringa","year":"2007","journal-title":"J Vasc Surg"},{"key":"R76-5-20210203","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0002-9149(03)00833-6","article-title":"Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at 6 months and at 1 year after treatment.","volume":"92","author":"Aronow","year":"2003","journal-title":"Am J Cardiol"},{"key":"R77-5-20210203","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(03)00010-X","article-title":"Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease.","volume":"114","author":"Mondillo","year":"2003","journal-title":"Am J Med"},{"key":"R78-5-20210203","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","article-title":"Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.","volume":"108","author":"Mohler","year":"2003","journal-title":"Circulation"},{"key":"R79-5-20210203","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1524-6175.2006.05636.x","article-title":"Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.","volume":"8","author":"Messerli","year":"2006","journal-title":"J Clin Hypertens"},{"issue":"suppl 2","key":"R80-5-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-200464002-00005","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial.","volume":"64","author":"Sever","year":"2004","journal-title":"Drugs"},{"key":"R81-5-20210203","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/FJC.0b013e31803d35ce","article-title":"Angiotensin II type I receptor expression in polymorphonuclear lymphocytes from high-risk subjects: changes after treatment with simvastatin.","volume":"49","author":"Marino","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"R82-5-20210203","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.atherosclerosis.2009.09.009","article-title":"Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension\u2014results from the EUTOPIA trial.","volume":"209","author":"Lorenzen","year":"2010","journal-title":"Atherosclerosis"},{"key":"R83-5-20210203","first-page":"613","article-title":"Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension.","volume":"67","author":"Si\u0144ski","year":"2009","journal-title":"Kardiol Pol"},{"key":"R84-5-20210203","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archinte.168.7.721","article-title":"Reduction in blood pressure with statins: results from the UCSD Statin study, a randomized trial.","volume":"168","author":"Golomb","year":"2008","journal-title":"Arch Intern Med"},{"key":"R85-5-20210203","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/01.HYP.0000259737.43916.42","article-title":"Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials.","volume":"49","author":"Strazzullo","year":"2007","journal-title":"Hypertension"},{"key":"R86-5-20210203","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejvs.2005.12.024","article-title":"Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth.","volume":"32","author":"Schouten","year":"2006","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R87-5-20210203","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1139\/Y09-085","article-title":"Atorvastatin mediates increases in intralesional BAX and BAK expression in human end-stage abdominal aortic aneurysms.","volume":"87","author":"Schweitzer","year":"2009","journal-title":"Can J Physiol Pharmacol"},{"key":"R88-5-20210203","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1538574409348352","article-title":"Atorvastatin modulates matrix metalloproteinase expression, activity, and signaling in abdominal aortic aneurysms.","volume":"44","author":"Schweitzer","year":"2010","journal-title":"Vasc Endovascular Surg"},{"key":"R89-5-20210203","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.atherosclerosis.2009.03.028","article-title":"Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall.","volume":"206","author":"Kajimoto","year":"2009","journal-title":"Atherosclerosis"},{"key":"R90-5-20210203","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1177\/009127009803801201","article-title":"Matrix metalloproteinases and abdominal aortic aneurysms: a potential therapeutic target.","volume":"38","author":"Sinha","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"R91-5-20210203","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejvs.2004.07.008","article-title":"A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery.","volume":"28","author":"Kertai","year":"2004","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R92-5-20210203","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.jvs.2010.01.028","article-title":"Preoperative statin therapy is associated with improved outcomes and resource utilization in patients undergoing aortic aneurysm repair.","volume":"51","author":"McNally","year":"2010","journal-title":"J Vasc Surg"},{"key":"R93-5-20210203","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jamcollsurg.2009.03.005","article-title":"Prehospital HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal aortic aneurysm.","volume":"209","author":"Feeney","year":"2009","journal-title":"J Am Coll Surg"},{"key":"R94-5-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2310\/6670.2006.00010","article-title":"Statin use is associated with reduced all-cause mortality after endovascular abdominal aortic aneurysm repair.","volume":"14","author":"Leurs","year":"2006","journal-title":"Vascular"},{"key":"R95-5-20210203","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-3-211-75718-5_59","article-title":"Role of statins in cerebral vasospasm.","volume":"104","author":"Sugawara","year":"2008","journal-title":"Acta Neurochir Suppl"},{"key":"R96-5-20210203","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.brainres.2009.09.064","article-title":"The 3-hydroxy-3-methyglutaryl A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits.","volume":"1303","author":"Lapchak","year":"2009","journal-title":"Brain Res"},{"key":"R97-5-20210203","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1161\/hs1201.099663","article-title":"Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease.","volume":"32","author":"Sterzer","year":"2001","journal-title":"Stroke"},{"key":"R98-5-20210203","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention.","volume":"8","author":"Amarenco","year":"2009","journal-title":"Lancet Neurol"},{"key":"R99-5-20210203","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-007-0080-2","article-title":"Prior statin use reduces mortality in intracerebral hemorrhage.","volume":"8","author":"Naval","year":"2008","journal-title":"Neurocrit Care"},{"key":"R100-5-20210203","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1161\/STROKEAHA.107.508341","article-title":"Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis.","volume":"39","author":"Sillberg","year":"2008","journal-title":"Stroke"},{"key":"R101-5-20210203","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1525-1497.1999.02109.x","article-title":"Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke.","volume":"14","author":"Warshafsky","year":"1999","journal-title":"J Gen Intern Med"},{"key":"R102-5-20210203","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00129784-200303060-00003","article-title":"Contrast nephropathy: an evidence-based approach to prevention.","volume":"3","author":"Kandzari","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"R103-5-20210203","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjmed.2005.03.031","article-title":"Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions.","volume":"118","author":"Khanal","year":"2005","journal-title":"Am J Med"},{"key":"R104-5-20210203","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.amjcard.2007.08.030","article-title":"Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.","volume":"101","author":"Patti","year":"2008","journal-title":"Am J Cardiol"},{"key":"R105-5-20210203","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/00063198-200309000-00007","article-title":"Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment.","volume":"9","author":"Ray","year":"2003","journal-title":"Curr Opin Pulm Med"},{"key":"R107-5-20210203","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.amjmed.2009.05.025","article-title":"Statins decrease the occurrence of venous thromboembolism in patients with cancer.","volume":"123","author":"Khemasuwan","year":"2010","journal-title":"Am J Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045415-201011000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:39:29Z","timestamp":1786041569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045415-201011000-00005"}},"subtitle":["A Comprehensive Review"],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":103,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0b013e3181f52a7f","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}